Adelo Acquires Dot I/O Health; Nigel Breakwell Joins as Managing Partner
Adelo, a precision health engagement and intelligence company, has officially acquired Dot I/O Health, a consultancy specializing in data science-driven pharmaceutical strategy. As a central component of this strategic acquisition, Nigel Breakwell, the co-founder and former Managing Partner of Dot I/O Health, has joined Adelo in the role of Managing Partner. Breakwell brings over thirty years of extensive experience in pharmaceutical strategy, communications, and consulting to the platform. His professional background includes significant leadership positions such as Joint CEO at Edelman UK and Managing Director at WCG (now Real Chemistry), following early career roles at Sanofi and MSD. The integration aims to bridge the gap between generated intelligence and practical pharmaceutical strategy implementation. Ben Randal, Strategy Lead at Adelo, emphasized that this move ensures their intelligence directly influences critical business decisions, particularly regarding high-value investments. Breakwell stated his focus will be on connecting intelligence to genuine strategy from global positioning to final implementation. This acquisition highlights Adelo's commitment to enhancing its strategic capabilities within the healthcare sector by incorporating specialized expertise in patient engagement and market access.
Wire timeline
Adelo Acquires Dot I/O Health; Nigel Breakwell Joins as Managing Partner
Adelo, a precision health engagement and intelligence company, has officially acquired Dot I/O Health, a consultancy specializing in data science-driven pharmaceutical strategy. As a central component of this strategic acquisition, Nigel Breakwell, the co-founder and former Managing Partner of Dot I/O Health, has joined Adelo in the role of Managing Partner. Breakwell brings over thirty years of extensive experience in pharmaceutical strategy, communications, and consulting to the platform. His professional background includes significant leadership positions such as Joint CEO at Edelman UK and Managing Director at WCG (now Real Chemistry), following early career roles at Sanofi and MSD. The integration aims to bridge the gap between generated intelligence and practical pharmaceutical strategy implementation. Ben Randal, Strategy Lead at Adelo, emphasized that this move ensures their intelligence directly influences critical business decisions, particularly regarding high-value investments. Breakwell stated his focus will be on connecting intelligence to genuine strategy from global positioning to final implementation. This acquisition highlights Adelo's commitment to enhancing its strategic capabilities within the healthcare sector by incorporating specialized expertise in patient engagement and market access.
PMLiVE